カテゴリ： GlobalData, アイルランド, 企業調査

Allergan Plc (AGN)：医療機器：M&Aディール及び事業提携情報

◆英語タイトル：Allergan Plc (AGN) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA904C2995
◆発行会社（調査会社）：GlobalData
◆発行日：2018年8月
◆ページ数：148
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アイルランド
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Allergan Plc (Allergan) is a specialty pharmaceutical company that develops and sells branded pharmaceuticals, biosimilar and over-the-counter (OTC) pharmaceutical products. It offers products in the areas of eye care, medical aesthetics, dermatology, central nervous system, gastroenterology, women’s health, urology and anti-infective therapeutic categories. The company sells its products to retailers, drug wholesalers and distributors, including national retail drug and food store chains, mail order retailers, hospitals, clinics, government agencies and managed healthcare providers such as health maintenance organizations and other institutions. It has operations in several countries across the Americas, Europe, Asia-Pacific, the Middle East and Africa. Allergan is headquartered in Dublin, Ireland.

Allergan Plc (AGN) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Allergan Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 8
Allergan Plc, Medical Equipment Deals By Type, 2012 to YTD 2018 9
Allergan Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 10
Allergan Plc, Medical Equipment, Deals By Market, 2012 to YTD 2018 11
Allergan Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 12
Allergan Plc, Medical Equipment, Deal Details 16
Asset Purchase 16
Allergan Acquires Rights to LiRIS from TARIS Biomedical for USD588 Million 16
Allergan Acquires Aline Hyaluronic Acid Thread Technology From Aline Aesthetics 17
LifeCell Acquires Adipose Tissue Injector From TauTona 18
Venture Financing 19
ForSight Vision5 Raises Additional USD4 Million Financingc 19
ForSight Vision5 Raises Additional USD6 Million in Financing 20
Colorescience Raises USD15 Million in Series B Venture Financing 21
ForSight Vision5 Raises US$15 Million In Series C Financing 22
Oculeve Raises US$17 Million In Venture Financing 23
AqueSys Raises US$43.6 Million In Series D Financing 24
Colorescience Raises US$10 Million In Series A Financing 26
ForSight Vision5 Raises US$9 Million In Series B-1 Financing 27
Anterios Raises US$8.5 Million In Venture Financing 28
Anterios Raises US$4.7 Million In Venture Financing 29
Oculeve Raises US$7.6 Million In Venture Financing 30
Topokine Therapeutics Raises Funds Through Venture Financing 31
Colorescience Raises US$15 Million In Venture Financing 32
Regado Biosciences Raises US$51 Million In Series E Financing 33
Oculeve Raises Additional US$0.2 Million In Venture Financing 35
ForSight Vision5 Raises US$8 Million In Venture Financing 36
Uteron Pharma Raises US$10.4 Million In Venture Financing 37
AqueSys Raises US$12 Million In Venture Financing 38
Uteron Pharma Raises US$19 Million In Venture Financing 39
Private Equity 40
TPG Capital Acquires Aptalis Pharma from Actavis 40
Partnerships 41
Medicines360 Enters Into Licensing Agreement With Actavis For Intrauterine Device 41
Enzymatica To Enter Into Licensing Agreement With Actavis For ColdZyme Mouth Spray 42
T2 Biosystems Enters into Agreement with Allergan 43
Allergan Enters into Co-Development Agreement with SonarMD 44
Syneron Medical and Allergan Enter into Agreement 45
Galderma Enters into Agreement with ZELTIQ Aesthetics 46
Advance Medical Enters Into Co-Marketing Agreement With Zeltiq Aesthetics For CoolSculpting System 47
Equity Offering 48
Allergan Files Registration Statement for Public Offering of Securities 48
Anterios Postpones IPO for up to USD54.6 Million 50
Actavis Raises USD5.06 Billion in Public Offering of Preferred Shares 51
Actavis Raises USD4.18 Billion in Public Offering of Shares 53
Regado Biosciences Completes Public Offering Of Shares For US$60 Million 55
Regado Biosciences Completes Private Placement Of Shares For US$20 Million 56
Regado Biosciences Completes Underwriters’ Exercise Of Over-Allotment Option For IPO For US$43 Million 57
Zeltiq Aesthetics Files Registration Statement For Public Offering Of Securities For US$75 Million 59
Forest Labs Plans Rights Offering Of Common Stock 60
Debt Offering 61
Allergan Raises USD763.3 Million in Public Offering of Notes Due 2019 61
Allergan Raises USD763.3 Million in Public Offering of 1.25% Notes Due 2024 62
Allergan Raises USD599.7 Million in Public Offering of 2.125% Notes Due 2029 63
Forest Lab Completes Private Placement Of Notes Due 2019 For US$1.05 Billion 64
Forest Lab Completes Private Placement Of Notes Due 2021 For US$750 Million 65
Forest Labs Completes Private Placement Of Notes Due 2021 For US$1.2 Billion 66
Asset Transactions 67
Novadaq to Acquire Rights to SPY Elite System from LifeCell 67
Apollo Endosurgery Completes Acquisition Of Obesity Intervention Division Of Allergan For Up To US$110 Million 68
Acquisition 70
Allergan to Acquire Elastagen 70
Allergan to Sell 10% Stake in Teva Pharma 71
Adcock Ingram to Acquire Genop 72
Allergan Sales to Acquire Keller Medical 73
Allergan Acquires ZELTIQ Aesthetics for USD2.48 Billion 74
Allergan Acquires LifeCell from Acelity for USD2.9 Billion 76
Allergan Acquires Tobira Therapeutics in Tender Offer 78
Carl Icahn Acquires Stake in Allergan 80
Allergan Acquires Anterios 81
Allergan Acquires AqueSys 82
Allergan Acquires Northwood Medical 83
Allergan Acquires Oculeve 84
Actavis Acquires Allergan for USD70.5 Billion 85
Actavis Completes Acquisition of Forest Labs for USD28 Billion 87
Forest Lab Completes Acquisition Of Aptalis Pharma From TPG Capital For US$2.9 Billion 89
Actavis Completes Acquisition Of Remaining 26.7% Stake In Zdravlje For Up To US$9.1 Million 91
Watson Pharma Acquires Uteron Pharma, Women’s Health Company, For Up To US$305 Million 92
SkinMedica Acquires Colorescience, Maker Of Skincare Products 94
Allergan Plc – Key Competitors 95
Allergan Plc – Key Employees 96
Allergan Plc – Locations And Subsidiaries 97
Head Office 97
Other Locations & Subsidiaries 97
Recent Developments 105
Financial Announcements 105
Jul 26, 2018: Allergan reports strong second quarter 2018 results including GAAP net revenues of $4.1 Billion 105
Apr 30, 2018: Allergan Reports 3% Increase in First Quarter 2018 GAAP Net Revenues to $3.7 Billion 108
Jan 08, 2018: Allergan Provides 2018 Preliminary Financial Outlook for Select Income Statement Categories and Other Updates at 36th Annual J. P. Morgan Conference 111
Nov 01, 2017: Allergan Reports Solid Top-Line Execution in Third Quarter 2017 with 11% Increase in GAAP Net Revenues to $4.03 Billion 112
Aug 03, 2017: Allergan Reports Continued Strong Execution in Second Quarter 2017 with 9% Increase in GAAP Net Revenues to $4.0 Billion 116
May 09, 2017: Allergan Reports Solid Start to 2017 with 5% Increase in First Quarter GAAP Net Revenues to $3.6 Billion 120
Feb 08, 2017: Allergan Reports Strong 2016 Finish with 7% Increase in GAAP Net Revenues to $3.9 Billion in Fourth Quarter 2016 124
Corporate Communications 128
Aug 08, 2018: Allergan appoints neurobiology expert Michael E Greenberg PhD to its Board of Directors as part of active board refreshment process 128
Jun 14, 2018: Allergan Continues Active Board Refreshment Process 129
May 03, 2018: John Davidson Elected to Allergan Board of Directors 130
Feb 05, 2018: Allergan Appoints Matthew M. Walsh As Executive Vice President and Chief Financial Officer 131
Dec 18, 2017: Allergan Announces Promotion of Wayne Swanton to Executive Vice President, Global Operations 132
Sep 11, 2017: The Allergan Foundation to Donate $150,000 to Support Hurricane Irma Relief Efforts 133
Jul 19, 2017: Joseph H. Boccuzi Appointed to Allergan Board of Directors 134
Apr 10, 2017: Allergan Receives 2017 ENERGY STAR Partner of the Year – Sustained Excellence Award from U.S. Environmental Protection Agency 135
Apr 06, 2017: Allergan Names Daphne Karydas as Senior Vice President of Global Investor Relations & Strategy 136
Feb 27, 2017: Lisa DeFrancesco, Vice President of Investor Relations, to Leave Allergan 137
Product News 138
Nov 08, 2017: Allergan to Present Dynamic Eye Care Data at American Academy of Ophthalmology Meeting in New Orleans 138
Oct 11, 2017: Allergan to Present Data From More Than 20 Abstracts at the 2017 Fall Clinical Dermatology Conference 139
Oct 05, 2017: Allergan Presents Data From Seventeen Abstracts At The 2017 American Society For Dermatologic Surgery Meeting In Chicago 140
May 04, 2017: Allergan to Present New Data at the 2017 American College of Obstetricians and Gynecologists (ACOG) Clinical and Scientific Meeting in San Diego 142
Jan 05, 2017: Allergan to Present at Goldman Sachs Healthcare CEOs Unscripted Conference and Provides Preliminary Comments on 2017 Outlook 143
Other Significant Developments 144
Jun 28, 2018: Allergan Eases Manual Data Entry and Contract Management Pains with Pramata’s Billing Accuracy Solution 144
Sep 25, 2017: New Study Showcases Economic Impact of Allergan Operations on French Economy 145
Sep 14, 2017: Industry Leaders Allergan and Sientra Invest in The American Society for Aesthetic Plastic Surgery for Breast Implant Research 146
Sep 12, 2017: Allergan Launches New Brilliant Distinctions Patient Loyalty Program 147
Appendix 148
Methodology 148
About GlobalData 148
Contact Us 148
Disclaimer 148

List of Tables
Allergan Plc, Medical Equipment, Key Facts, 2017 2
Allergan Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Allergan Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 8
Allergan Plc, Medical Equipment Deals By Type, 2012 to YTD 2018 9
Allergan Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 10
Allergan Plc, Deals By Market, 2012 to YTD 2018 11
Allergan Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 12
Allergan Acquires Rights to LiRIS from TARIS Biomedical for USD588 Million 16
Allergan Acquires Aline Hyaluronic Acid Thread Technology From Aline Aesthetics 17
LifeCell Acquires Adipose Tissue Injector From TauTona 18
ForSight Vision5 Raises Additional USD4 Million Financingc 19
ForSight Vision5 Raises Additional USD6 Million in Financing 20
Colorescience Raises USD15 Million in Series B Venture Financing 21
ForSight Vision5 Raises US$15 Million In Series C Financing 22
Oculeve Raises US$17 Million In Venture Financing 23
AqueSys Raises US$43.6 Million In Series D Financing 24
Colorescience Raises US$10 Million In Series A Financing 26
ForSight Vision5 Raises US$9 Million In Series B-1 Financing 27
Anterios Raises US$8.5 Million In Venture Financing 28
Anterios Raises US$4.7 Million In Venture Financing 29
Oculeve Raises US$7.6 Million In Venture Financing 30
Topokine Therapeutics Raises Funds Through Venture Financing 31
Colorescience Raises US$15 Million In Venture Financing 32
Regado Biosciences Raises US$51 Million In Series E Financing 33
Oculeve Raises Additional US$0.2 Million In Venture Financing 35
ForSight Vision5 Raises US$8 Million In Venture Financing 36
Uteron Pharma Raises US$10.4 Million In Venture Financing 37
AqueSys Raises US$12 Million In Venture Financing 38
Uteron Pharma Raises US$19 Million In Venture Financing 39
TPG Capital Acquires Aptalis Pharma from Actavis 40
Medicines360 Enters Into Licensing Agreement With Actavis For Intrauterine Device 41
Enzymatica To Enter Into Licensing Agreement With Actavis For ColdZyme Mouth Spray 42
T2 Biosystems Enters into Agreement with Allergan 43
Allergan Enters into Co-Development Agreement with SonarMD 44
Syneron Medical and Allergan Enter into Agreement 45
Galderma Enters into Agreement with ZELTIQ Aesthetics 46
Advance Medical Enters Into Co-Marketing Agreement With Zeltiq Aesthetics For CoolSculpting System 47
Allergan Files Registration Statement for Public Offering of Securities 48
Anterios Postpones IPO for up to USD54.6 Million 50
Actavis Raises USD5.06 Billion in Public Offering of Preferred Shares 51
Actavis Raises USD4.18 Billion in Public Offering of Shares 53
Regado Biosciences Completes Public Offering Of Shares For US$60 Million 55
Regado Biosciences Completes Private Placement Of Shares For US$20 Million 56
Regado Biosciences Completes Underwriters' Exercise Of Over-Allotment Option For IPO For US$43 Million 57
Zeltiq Aesthetics Files Registration Statement For Public Offering Of Securities For US$75 Million 59
Forest Labs Plans Rights Offering Of Common Stock 60
Allergan Raises USD763.3 Million in Public Offering of Notes Due 2019 61
Allergan Raises USD763.3 Million in Public Offering of 1.25% Notes Due 2024 62
Allergan Raises USD599.7 Million in Public Offering of 2.125% Notes Due 2029 63
Forest Lab Completes Private Placement Of Notes Due 2019 For US$1.05 Billion 64
Forest Lab Completes Private Placement Of Notes Due 2021 For US$750 Million 65
Forest Labs Completes Private Placement Of Notes Due 2021 For US$1.2 Billion 66
Novadaq to Acquire Rights to SPY Elite System from LifeCell 67
Apollo Endosurgery Completes Acquisition Of Obesity Intervention Division Of Allergan For Up To US$110 Million 68
Allergan to Acquire Elastagen 70
Allergan to Sell 10% Stake in Teva Pharma 71
Adcock Ingram to Acquire Genop 72
Allergan Sales to Acquire Keller Medical 73
Allergan Acquires ZELTIQ Aesthetics for USD2.48 Billion 74
Allergan Acquires LifeCell from Acelity for USD2.9 Billion 76
Allergan Acquires Tobira Therapeutics in Tender Offer 78
Carl Icahn Acquires Stake in Allergan 80
Allergan Acquires Anterios 81
Allergan Acquires AqueSys 82
Allergan Acquires Northwood Medical 83
Allergan Acquires Oculeve 84
Actavis Acquires Allergan for USD70.5 Billion 85
Actavis Completes Acquisition of Forest Labs for USD28 Billion 87
Forest Lab Completes Acquisition Of Aptalis Pharma From TPG Capital For US$2.9 Billion 89
Actavis Completes Acquisition Of Remaining 26.7% Stake In Zdravlje For Up To US$9.1 Million 91
Watson Pharma Acquires Uteron Pharma, Women's Health Company, For Up To US$305 Million 92
SkinMedica Acquires Colorescience, Maker Of Skincare Products 94
Allergan Plc, Key Competitors 95
Allergan Plc, Key Employees 96
Allergan Plc, Other Locations 97
Allergan Plc, Subsidiaries 97

List of Figures
Allergan Plc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Allergan Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Allergan Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Allergan Plc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Allergan Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 8
Allergan Plc, Medical Equipment, Deals by Type, 2012 to YTD 2018 9
Allergan Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 10
Allergan Plc, Medical Equipment, Deals by Market, 2012 to YTD 2018 11

★海外企業調査レポート[Allergan Plc (AGN)：医療機器：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Apollo Education Group Inc：企業の戦略的SWOT分析
    Apollo Education Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Nampak Limited：企業の戦略・SWOT・財務情報
    Nampak Limited - Strategy, SWOT and Corporate Finance Report Summary Nampak Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Halliburton Company：企業の戦略・SWOT・財務情報
    Halliburton Company - Strategy, SWOT and Corporate Finance Report Summary Halliburton Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • National Beverage Corp. (FIZZ)：企業の財務・戦略的SWOT分析
    National Beverage Corp. (FIZZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Wageningen University-製薬・医療分野：企業M&A・提携分析
    Summary Wageningen University (WU), a subsidiary of Wageningen University and Research Centre, is an education and research institution. The university offers bachelors’, masters’ and PhD programs. It specializes in healthy food and living environment domain. WU offers various courses in bachelor of …
  • The Empire District Electric Company-エネルギー分野：企業M&A・提携分析
    Summary The Empire District Electric Company (EDE), a subsidiary of Liberty Utilities Co., is a regulated utility that provides electricity, natural gas, and water services. The company generates, procures, transmits, distributes, and sells electricity. It generates electricity from natural gas, coa …
  • Transgenomic Inc (TBIO)-医療機器分野：企業M&A・提携分析
    Summary Transgenomic Inc (Transgenomic) is a developer and provider of diagnostic tools and services. The company’s products include ICEme Kits, and genetic assays and platforms. It offers genetic assays and platforms such as PCR reagents, chromatography, genetic analysis kits, hanabi cytogenetic sy …
  • NetScout Systems, Inc. (NTCT)：企業の財務・戦略的SWOT分析
    NetScout Systems, Inc. (NTCT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Dialog Semiconductor plc (DLG)-エネルギー分野：企業M&A・提携分析
    Summary Dialog Semiconductor plc (Dialog) is a supplier of motor control ICs for automotive applications. The company’s product portfolio includes integrated power management, AC/DC power conversion, solid state lighting (SSL), Bluetooth low energy, mixed signal integrated circuits (ICs), hand-held …
  • Amunix Operating Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Amunix Operating Inc (Amunix) is a biotechnology company that discovers and develops long-acting protein-based therapeutics. The company develops protein and peptide therapeutics. It uses its proprietary technology platform XTEN, a proprietary recombinant polypeptide that consists of natural …
  • Electromagnetic Geoservices ASA (EMGS)：企業の財務・戦略的SWOT分析
    Summary Electromagnetic Geoservices ASA (EMGS) is an oil and gas service provider that explores workflow working with seismic, petrophysical and geologic data. The company gathers controlled source electromagnetic data and conduct modeling, integration, interpretation. Its technology finds applicati …
  • Wns (Holdings) Limited：企業の戦略・SWOT・財務分析
    Wns (Holdings) Limited - Strategy, SWOT and Corporate Finance Report Summary Wns (Holdings) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Medherant Ltd：企業の製品パイプライン分析
    Summary Medherant Ltd (Medherant) is a transdermal drug delivery patch company. The company develops and commercializes novel technologies for delivery of drugs through the skin using expertise in bioadhesives and polymer chemistry to treat pain, Alzheimer's disease, and for smoking cessation, hormo …
  • Agilent Technologies Inc (A)：企業の財務・戦略的SWOT分析
    Agilent Technologies Inc (A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • BOC Aviation Limited (2588)：企業の財務・戦略的SWOT分析
    BOC Aviation Limited (2588) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • PetroNeft Resources plc (P8ET)：石油・ガス：M&Aディール及び事業提携情報
    Summary PetroNeft Resources Plc (PetroNeft) is an upstream oil and gas company. It carries out exploration, development and production of oil and natural gas. The company mainly focuses on oil rich Western Siberia zone in Russia. PetroNeft’s asset base comprises of 50% interest each in License 61 an …
  • Nuclear Decommissioning Authority：企業の戦略的SWOT分析
    Nuclear Decommissioning Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Federal Grid Company of Unified Energy System (FEES)：電力：M&Aディール及び事業提携情報
    Summary Federal Grid Company of Unified Energy System (FGC UES), a subsidiary of Rosseti, is an energy company. It operates and manages unified national electricity transmission grid system. The company transmits electricity to distribution grid companies, large commercial end customers and retail e …
  • Teleflex Inc (TFX)：医療機器：M&Aディール及び事業提携情報
    Summary Teleflex Inc (Teleflex) designs, develops, manufactures, and distributes disposable medical devices for use in critical care and surgery. Its major products include circuits, masks and bags, endotracheal tubes, pain pumps, supraglottic airways, catheters, adaptor and connectors. The company’ …
  • Mediware Information Systems Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Mediware Information Systems Inc (Mediware), a subsidiary of TPG Capital is a healthcare solutions company that designs, develops and commercializes specialized healthcare software. It provides software to healthcare and human service providers and payers. The company’s portfolio of solution …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆